# Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India

> **NCT05040126** · PHASE3 · UNKNOWN · sponsor: **Tuberculosis Research Centre, India** · enrollment: 400 (estimated)

## Conditions studied

- Pre-Extensively Drug-Resistant Pulmonary TB
- Treatment Intolerant Multidrug-Resistant Pulmonary TB
- Non-responsive Multidrug-Resistant Pulmonary TB

## Interventions

- **DRUG:** Linezolid
- **DRUG:** Bedaquiline
- **DRUG:** Pretomanid

## Key facts

- **NCT ID:** NCT05040126
- **Lead sponsor:** Tuberculosis Research Centre, India
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-07
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2024-01-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040126, "Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05040126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*